Arranta Bio, a microbiome contract development and manufacturing organization (CDMO), has unveiled plans to invest $100 million to build end-to-end capacity as the first dedicated microbiome CDMO.
 
At the same time, the company has strengthened its senior leadership team with the addition of David Stevens as chief operations officer and Jason Rahal as senior vice president of business development.
 

As chief operations officer, Mr. Stevens will be responsible for driving the continued growth of Arranta’s operations, including the ongoing expansion of the company’s microbiome process development center of excellence in Gainesville, FL as well as operationalizing Arranta’s new best-in-class GMP facility in Watertown, MA. He brings over 20 years of broad operational and commercial experience in the CRO and CDMO sectors, most recently, serving as the senior vice president and head of AMRI’s drug product business unit where he had responsibility for sales and operations.
 
Mr. Rahal has over 25 years of experience in biotechnology. Prior to joining Arranta as senior vice president of business development, he was a member of the senior management team at Cobra Biologics, a CDMO providing ATMP services including Live Biotherapeutic Products (LBPs) with facilities in the UK and Sweden.
 
“I am delighted to have two experienced leaders join Arranta Bio’s senior team as we continue to build out our organization and invest in facilities as the leading end-to-end dedicated CDMO supporting microbiome pioneers with our services,” said Mark Bamforth, president and chief executive officer, Arranta.